Home
Helixmith

Helixmith Market Share Analysis for August 2026

Health > Health Conditions and Concerns

Domainhelixmith.com

Year Founded1996

Employees51 - 200

Annual Revenue--

Helixmith

Helixmith (including company regionals)

helixmith.com

See more website traffic and engagement information

Total visits to Helixmith's top domains

Understand Helixmith market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

helixmith.com1.9K

See more with Sales Intelligence

Avg. visit duration in Helixmith's top domains

Analyze Helixmith engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

helixmith.com--

See more with Sales Intelligence

Avg. pageviews on Helixmith's top domains

See how Helixmith keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

helixmith.com1.05

See more with Sales Intelligence

Helixmith top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Helixmith

These are the website technologies, by industry, used by Helixmith top domains

eCommerce (2)

Swap

Email Services (1)

Microsoft Exchange Online

Mobile (1)

Meta Viewport

Other (1)

Google API

More Technologies

1

See all

News & Signals from Helixmith

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsHelixmith Co., Ltd. launched second phase 3 trial for DPN, REGAiN-1A on Dec 31st '22.Helixmith launched a second phase 3 trial for DPN, REGAiN-1A (VMDN-003-2), in the US and are targeting release of top line results by the end of 2022.

NewsHelixmith Co., Ltd. launched Phase 1/2a study involving Korean patients with Charcot-Marie-Tooth disease on Nov 13th '20.Gene therapy developer Helixmith announced today that its Phase 1/2a study involving Korean patients with Charcot-Marie-Tooth disease (CMT) has passed 50% of its enrollment target.

Newsworldwide.com signs new client Helixmith Co., Ltd..Helixmith has selected Worldwide Clinical Trials to run a planned Phase 2 study of Engensis ( VM202 ), its potential gene therapy for amyotrophic lateral sclerosis (ALS), according to a company press release.